Levels of adenosine deaminase and dipeptidyl peptidase IV in patients with panic disorder

Turk Psikiyatri Dergisi

Volumn 19, Issue 2, 2008, Pages

  Yolaç Yarpuz, Asli ^a   Yilmaz, Ayşegül ^a   Soykan, Atilla ^a   Elgün, Serenay ^a   Kumbasar, Hakan ^a  

^a NONE

Author keywords

Adenasine deaminase; Dipeptidyl peptidase IV; Immune system; Panic disorder

Indexed keywords

EID: 51749107006     PISSN: 13002163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Akdemir A, Örsel SD, Daǧ I et al. (1996) Hamilton Depresyon Derecelendirme Ölçeǧi (HDDÖ)'nin geȩrliǧi-güvenirliǧi ve klinikte kullanimi. Psikiyatri Psikofarmakoloji Dergisi, 4:251-259.
2. Andreoli A, Keller SE, Rabaeus M, Zaugg L, Garrone G, Taban C (1992) Immunity, major depression, and panic disorder comorbidity. Biol Psychiatry, 31:896-908.
3. Aydin N, Kirkpinar I (2001) Psikiyatrik Bozukluklar ve Otoimmünite. Erzuruh Yayinlari, p.10-15.
4. Brambilla F, Bellodi L, Perna G, Battaglia M, Sciuto G, Diaferia G (1992) Psychoimmunoendocrine aspects of panic disorder. Neuropsychobiology, 26: 12-22.
5. Çorapçioǧlu A, Aydemir Ö, Yildiz M et al. (1999) DSM-IV Eksen I Bozukluklari (SCID-I) Için Yapilandirilmiş Klinik Görüşme, Klinik Versiyon. Ankara, Hekimler Yayin Birligi.
6. Da Cunha JG (1991) Adenosine deaminase. A pluridisciplinary enzyme. Acta Med Port, 4:315-323.
7. Elgün S, Keskinege A, Akan H, Karaca L (1999a) Serum dipeptidyl peptidase IV activity correlates with the T cell CD26 antigen Clin Chem Lab Med, 37(8):839-40.
8. Elgün S, Keskinege A, Kumbasar H (1999b) Dipeptidyl peptidase IV and adenosine deaminase activity, decrease in depression. Psychoneuroendocrinology, 24:823-832.
9. Elgün S, Keskinege A, Yilmaz E (2001) Tissue dipeptidyl peptidase IV and adenosine deaminase activities in benign prostatic hypertrophyand prostate cancer. Cancer Research Therapy and Control, 11:107-111.
10. First MB, Spitzer RL, Gibbon M (1997) Structured Clinical Interview for DSM-IV Clinical Version (SCID-I/CV). Washington D.C, American Psychiatric Press.
11. Galinowski A (1993) Stress and panic. Immunologic aspects. Encephale, 19 (Spec No 1):147-151.
12. Gladkevich A, Kauffman HF, Korf J (2004) Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry, 28:559-576.
13. Hamilton M (1959) The assesment of anxiety states by rating. Br J Med Psychol, 32:50-55.
14. Hamilton M (1967) Development of a rating scale for primary deppressie illness. Br J Soc Clin Psychol, 6:278-296.
15. Herken H, Akyol O, Yilmaz R, Tutkun H, Savas H, Ozen ME, Kalenderoglu A, Gulec M (2006) Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase: alterations by antidepressant treatment. Hum Psychopharmacol Clin Exp, 21: 53-59.
16. Hildebrandt M, Rose M, Mayr C, Schuler C, Reutter W, Salama A (1999) Alterations in expression and in serum activity of dipeptidyl peptidase IV in patients with hiporectic eating disorders. Scand J Immunol, 50: 536-540.
17. Hu T, Zhou X, Zhang J (1999) The activities of proteolytic enzymes in dental plaque of patients in different age-sex groups. Hua Xi Yi Ke Da Xue Xue Bao, 30:368-369, 378.
18. Kim Y, Park Q, Yu B (2004) Changes in lymphocyte subsets after short-term pharmacotherapy in patients with panic disorder. Psychiatry Research, 128:183-190.
19. Koh KB, Lee Y (2004) Reduced anxiety level by therapeutic interventions and cell-mediated immunity in panic disorder patients. Psychother Psychosom, 73:286-92.
20. Kokai M, Kashiwamura S, Okamura H, Ohara K, Morita Y (2002) Plasma interleukin-18 levels in patients with psychiatric disorders. J Immunother, 25 (Suppl 1):S68-71.
21. Kovalenko PA, Hoven CW, Wu P, Wicks J, Mandell DJ, Tiet Q, Aust NZ (2001) Association between allergy and anxiety disorders in youth. J Psychiatry, 35:815-821.
22. Livnat S, Felten S, Carlson S, Bellinger DL, Felten D (1985) Involvement of peripheral and central catecholamine systems in neural-immune interactions. J Neuroimmunol, 10: 5-30.
23. Mackiewicz M, Nikonova EV, Zimmermann JE, Romer MA, Cater J, Galante RJ, Pack (2006) Age-related changes in adenosine metabolic enzymes in sleep/ wake regulatory areas of the brain. Neurobiol Aging, 27:351-360.
24. Maes M, Meester I, Vanhoof G, Scharpe S, Bosmans E, Vandervorst C, Verkerk R, Minner B, Suy E, Raus J (1991) Decreased serum dipeptidyl peptidase IV activity in major depression. Biol Psychiatry, 30: 577-586.
25. Maes M, Meester I, Scharpe S, Desnder R, Ranjan R, Meltzer HY (1996) Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs. Acta Psychiatr Scand, 93:1-8.
26. Maes M, Chiavetto LB, Bignotti S, Tura JB, Pioli R, Boin F, Kenis G, Bosmans E (2000) Effects of atypical antipsychotics on the inflamatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. European Neuropsychopharmachology, 10: 119-124.
27. Maes M, Capuron L, Ravaud A, Gualde N, Bosmans E, Egyed B (2001a) Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving IL-2 based immunotherapy. Neuropsychopharmacology, 24: 130-140.
28. Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Meltzer H (2001b) Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry, 6:475-480.
29. Maes M, Bonaccorso S (2004) Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C. Acta Psychiatr Scand, 109:126-131.
30. Nagatsu T, Hino M, Fuyamada H, Hayakawa T, Sakakibara S (1976) New chromogenic substrates for x-prolyl dipeptidyl aminopeptidase. Anal. Biochem, 74:466-476.
31. O'Neill B, Leonard BE (1990) Abnormal zymosan-induced neutrophil chemiluminescence as a marker of depression. J Affect Disord, 19:265-272.
32. Oosthuizen HM, Ungerer JPJ, Bissbort SH (1993) Kinetic determination of serum adenosine deaminase. Clin Chem, 39; 2182-2185.
33. Park JE, Kim SW, Park Q, Jeong DU, Yu BH (2005) Lymphocyte subsets and mood states in panic disorder patients. J Korean Med Sci, 20:215-219.
34. Ramesh C, Yeragani VK, Balon R, Pohl R (1991) A comparative study of immune status in panic disorder patients and controls. Acta Psychiatr Scand, 84:396-397.
35. Rapaport MH, Stein MB (1994) Serum cytokine and soluble interleukin-2 receptors in patients with panic disorder. Anxiety, 1:22-25.
36. Rapaport MH (1998) Circulating lymphocyte phenotypic surface markers in anxiety disorder patientsand normal volunteers. Biol Psychiatry, 43:458-63.
37. Schiepers OJ, Wichers MC, Maes M (2005) Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry, 29:201-17.
38. Schleifer SJ, Keller SE, Bartlett JA (2002) Panic disorder and immunity: few effects on circulating lymphocytes, mitogen response, and NK cell activity. Brain Behav Immun, 16:698-705.
39. Schmidt-Traub S, Bamler KJ (1997) The psychoimmunological association of panic disorder and allergic reaction. Br J Clin Psychol, 36 (Pt 1):51-62.
40. Schwarz J, Chiang S, Müller N, Ackenheil M (2001) T-helper-1 and T-helper-2 Responses in Psychiatric Disorders. Brain Behav Immun, 15, 340-370.
41. Sperner-Unterweger B (2005) Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. Drugs, 65:1493-520.
42. Van West D, Monteleone P, Di Lieto A, Meester I, Durinx C, Scharpe S (2000) Lowered serum dipeptidyl peptidase IV activity in patients with anorexia and blumia nervosa. Eur Arch Psychiatry Clin Neurosci, 250: 86-92.
43. Weizman R, Laor N, Wiener Z, Wolmer L, Bessler H (1999) Cytokine production in panic disorder patients. Clin Neuropharmacol, 22(2):107-9.
44. Yazici MK, Demir B, Tanriverdi N et al. (1998) Hamilton anksiyete deǧerlendirme ölçeǧi, deǧerlendiriciler arasi güvenirlik ve geçerlik çalişmasi. Turk Psikiyatri Derg 9:114-117.